GARS1 and cancer: Professors Schimmel and Yang at the Scripps Research Institute disclosed four different glycylsulfamoyladenosine derivatives (GlySAs, Figure 13) as human glycyl-tRNA synthetase (GlyRS) inhibitors for cancer therapy by lowering neddylation [49].